Wutke K, Scheibner K
Folia Haematol Int Mag Klin Morphol Blutforsch. 1983;110(2):218-30.
Punctures of the pelvic crest made in 45 patients with CLL (25 men, 20 women, mean age 58.7 years) were classified according to the type of lymphatic bone-marrow infiltrations which can be identified histomorphologically. Four different types were distinguished: 1. interstitial type (lymphatic infiltration of bone-marrow tracts, with lipocytes being present) - 11 cases 2. nodular type (nodular infiltration, free bone-marrow tracts) - 5 cases 3. mixed type (combination of interstitial and nodular type) - 11 cases 4. diffuse type (original haematopoiesis and fat cells have been displaced, type A: purely diffuse type; type B: diffuse + nodular) - 18 cases The statistical analysis of survival curves reveals significant differences in the probability for survival to be met with in types with morphologically limited bone-marrow infiltration in the sense of a proceeding deterioration of prognosis in the following order: interstitial, nodular, mixed, and diffuse type. In addition, a statistically significant correlation existing between the non-diffuse infiltration types and clinical early stages (RAI 0 to II) on the one hand, and the diffuse type and clinical late stages (RAI III and IV) on the other hand, could be identified. In the course of CLL the different types of lymphatic bone-marrow infiltration apparently reflect different degrees of lymphocyte accumulation or proliferation respectively. Because of their significance the histomorphological bone-marrow findings should be included in the therapy planning for CLL.
对45例慢性淋巴细胞白血病患者(25例男性,20例女性,平均年龄58.7岁)进行的髂嵴穿刺,根据组织形态学可识别的淋巴骨髓浸润类型进行分类。区分出四种不同类型:1. 间质型(骨髓束的淋巴浸润,伴有脂肪细胞)——11例;2. 结节型(结节浸润,骨髓束游离)——5例;3. 混合型(间质型和结节型的组合)——11例;4. 弥漫型(原始造血和脂肪细胞被取代,A型:纯弥漫型;B型:弥漫+结节型)——18例。生存曲线的统计分析显示,从预后逐渐恶化的意义上讲,骨髓浸润形态学受限的类型在生存概率上存在显著差异,顺序如下:间质型、结节型、混合型和弥漫型。此外,一方面可以确定非弥漫性浸润类型与临床早期阶段(RAI 0至II)之间存在统计学显著相关性,另一方面弥漫型与临床晚期阶段(RAI III和IV)之间也存在相关性。在慢性淋巴细胞白血病病程中,不同类型的淋巴骨髓浸润显然分别反映了淋巴细胞积累或增殖的不同程度。鉴于其重要性,组织形态学骨髓检查结果应纳入慢性淋巴细胞白血病的治疗计划中。